Biotechnology Assets (XMAD:BST) Tariff Resilience Score: 0/10 (As of Jun. 30, 2026)


XMAD:BST Biotechnology Assets SA XMAD:BST
22 GF Score
Price €0.24
GF Value €0.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Tariff Resilience Score?

Biotechnology Assets has the Tariff Resilience Score of 0, which implies that the company might have .

Biotechnology Assets has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biotechnology Assets might have .

Biotechnology Assets  (XMAD:BST) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biotechnology Assets Tariff Resilience Score Related Terms

XMAD:BST
22GF Score
Biotechnology Assets SA XMAD:BST
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.24 is trading 21.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

  • Tariff Resilience Score: 0
  • GF Value™: €0.30 vs. price of €0.24 (21.7% below fair value)
  • GF Score™: 22/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
22GF Score

Get the complete analysis for XMAD:BST

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.30
GF Value